NCT02398058 - Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2014

Primary Completion Date

December 1, 2019

Study Completion Date

December 1, 2019

Conditions

Soft Tissue SarcomaBone Tumor

Interventions

DRUG

trabectedin

trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks

DRUG

olaparib

olaparib will be administered in a continuous daily dose every 12 hours

Trial Locations (3)

Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo

Istituto Nazionale Tumori - Unit of Medical Oncology, Milan

Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna